Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  AB Science    AB   FR0010557264

AB SCIENCE

(AB)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

AB Science provides clarification regarding the article published yesterday in the newspaper Les Echos related to the investigation by the French market authorities

share with twitter share with LinkedIn share with facebook
share via e-mail
11/22/2019 | 02:17am EDT

Paris, November 22, 2019, 8.15am

Clarification regarding the article published yesterday in the newspaper Les Echos related to the investigation by the French market authorities

AB Science SA (Euronext - FR0010557264 - AB) has taken note of the article published yesterday in the newspaper Les Echos regarding an investigation led by the Financial Markets Authority (Autorité des Marchés Financiers or AMF) related to AB Science financial information and market trading.

AB Science reminds that this investigation which started in 2017 was disclosed when the Company released its annual financial report for the fiscal year ended December 31, 2018.

AB Science is puzzled to read in the press an inaccurate and unfounded statement of the AMF investigators, in violation of the rights of the Company and its management, despite the fact that the investigation is still ongoing and that no formal grievances have been notified.

AB Science, which does not intend to comment on an ongoing investigation, reminds that the facts outlined in this article are formally contested and that the management of the Company is totally confident about the outcome of this investigation.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.

AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, and inflammatory diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website: www.ab-science.com.

Forward-looking Statements - AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in the Chapter 4 "Risk Factors" of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Attachment

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AB SCIENCE
03/12SCIENCE : AB Science will present results from its Phase 3 AB07015 study in seve..
GL
03/09SCIENCE : Summary of webcast with Key Opinion Leaders on masitinib Phase 2B/3 re..
PU
03/09SCIENCE : AB Science is providing a summary of the live webcast held on 06 March..
GL
03/09AB Science is providing a summary of the live webcast held on 06 March 2020 w..
GL
03/05AB Science will host a live webcast on masitinib in Progressive Forms of Mult..
GL
03/02SCIENCE : AB Science announces a new fundraising of EUR 12.3 million
GL
03/02AB Science will host a live webcast on masitinib in Progressive Forms of Mul..
GL
03/02SCIENCE : AB Science will host a live webcast on masitinib in Progressive Forms ..
GL
02/20AB Science announces positive top-line Phase 2B/3 results for oral masitinib ..
GL
01/08AB SCIENCE : announces that FDA green-lights U.S. patient enrollment in masitini..
AQ
More news
Financials (EUR)
Sales 2019 1,50 M
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -
Capi. / Sales2019 201x
Capi. / Sales2020 216x
Capitalization 302 M
Chart AB SCIENCE
Duration : Period :
AB Science Technical Analysis Chart | AB | FR0010557264 | MarketScreener
Technical analysis trends AB SCIENCE
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 10,00  €
Last Close Price 6,78  €
Spread / Highest target 47,5%
Spread / Average Target 47,5%
Spread / Lowest Target 47,5%
EPS Revisions
Managers
NameTitle
Alain Moussy Chairman, CEO & Scientific Director
Laurent Guy Chief Financial Officer
Christian Fassotte Global Chief Medical Officer
Antonello Cervone Director-Information Technology
Edita Dolimier Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
AB SCIENCE26.02%335
MERCK KGAA-13.93%43 714
KYOWA KIRIN CO., LTD.4.53%12 422
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD13.36%10 484
JAZZ PHARMACEUTICALS PLC-35.05%5 443
BETTA PHARMACEUTICALS CO., LTD.0.44%3 972